Arvinas (NASDAQ:ARVN) Insider Sells $110,413.52 in Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Noah Berkowitz sold 11,108 shares of Arvinas stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,413.52. Following the completion of the transaction, the insider owned 191,395 shares in the company, valued at $1,902,466.30. This trade represents a 5.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Noah Berkowitz also recently made the following trade(s):

• On Wednesday, March 18th, Noah Berkowitz sold 6,435 shares of Arvinas stock. The shares were sold at an average price of $11.10, for a total value of $71,428.50.
• On Friday, February 13th, Noah Berkowitz sold 5,685 shares of Arvinas stock. The shares were sold at an average price of $11.89, for a total value of $67,594.65.

Arvinas Trading Up 3.1%

Shares of ARVN traded up $0.30 during mid-day trading on Wednesday, hitting $9.87. The company’s stock had a trading volume of 787,117 shares, compared to its average volume of 855,453. The firm has a 50-day simple moving average of $11.21 and a 200 day simple moving average of $11.68. The firm has a market capitalization of $636.81 million, a P/E ratio of -7.71 and a beta of 1.79. Arvinas, Inc. has a 1-year low of $5.90 and a 1-year high of $14.51.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.05. The business had revenue of $15.60 million during the quarter, compared to analysts’ expectations of $16.61 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The company’s quarterly revenue was down 91.7% compared to the same quarter last year. During the same period last year, the firm earned $1.14 EPS. As a group, sell-side analysts predict that Arvinas, Inc. will post -3.25 EPS for the current fiscal year.

Arvinas News Roundup

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a buy rating, suggesting meaningful upside from current levels. BTIG raises Arvinas price target
• Positive Sentiment: Arvinas and Pfizer struck a licensing deal with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant), bringing in $85 million upfront and transition payments plus up to $320 million in additional milestones and royalties. Arvinas and Pfizer deal with Rigel
• Positive Sentiment: The company said VEPPANU became the first FDA-approved PROTAC, which validates Arvinas’ drug-degradation platform and supports its pipeline story. Arvinas Q1 2026 results and corporate update
• Neutral Sentiment: First-quarter results were mixed: Arvinas reported a smaller-than-expected loss of $0.90 per share, but revenue of $15.6 million missed estimates and fell sharply from a year ago. Arvinas Q1 earnings report
• Neutral Sentiment: Investors are also watching pre-earnings commentary and transcript coverage, but these items appear more informational than market-moving on their own. Arvinas earnings call transcript
• Negative Sentiment: Despite the product and licensing progress, Arvinas remains unprofitable with weak revenue trends, which may temper enthusiasm for the stock’s longer-term fundamentals. Arvinas earnings expectations

Wall Street Analyst Weigh In

Several analysts have recently commented on ARVN shares. Wall Street Zen cut Arvinas from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Citigroup raised their price target on Arvinas from $21.00 to $24.00 and gave the company a “buy” rating in a report on Monday, May 4th. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Zacks Research cut Arvinas from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Finally, Truist Financial set a $10.00 price objective on Arvinas in a report on Wednesday, March 18th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $15.14.

Hedge Funds Weigh In On Arvinas

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its holdings in Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after purchasing an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board increased its position in Arvinas by 109.4% during the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after buying an additional 3,500 shares in the last quarter. State of Wyoming purchased a new position in Arvinas during the third quarter worth $68,000. Aster Capital Management DIFC Ltd purchased a new position in Arvinas during the third quarter worth $92,000. Finally, Jain Global LLC purchased a new position in Arvinas during the third quarter worth $95,000. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.